Literature DB >> 12537523

The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.

Aiden A Flynn1, R Barbara Pedley, Alan J Green, Jason L Dearling, Ethaar El-Emir, Geoffrey M Boxer, Robert Boden, Richard H J Begent.   

Abstract

The therapeutic efficacy of radiolabeled antibody fragments can be limited by nephrotoxicity, particularly when the kidney is the major route of extraction from the circulation. Conventional dose estimates in kidney assume uniform dose deposition, but we have shown increased antibody localization in the cortex after glomerular filtration. The purpose of this study was to measure the radioactivity in cortex relative to medulla for a range of antibodies and to assess the validity of the assumption of uniformity of dose deposition in the whole kidney and in the cortex for these antibodies with a range of radionuclides. Storage phosphor plate technology (radioluminography) was used to acquire images of the distributions of a range of antibodies of various sizes, labeled with 125I, in kidney sections. This allowed the calculation of the antibody concentration in the cortex relative to the medulla. Beta-particle point dose kernels were then used to generate the dose-rate distributions from 14C, 131I, 186Re, 32P and 90Y. The correlation between the actual dose-rate distribution and the corresponding distribution calculated assuming uniform antibody distribution throughout the kidney was used to test the validity of estimating dose by assuming uniformity in the kidney and in the cortex. There was a strong inverse relationship between the ratio of the radioactivity in the cortex relative to that in the medulla and the antibody size. The nonuniformity of dose deposition was greatest with the smallest antibody fragments but became more uniform as the range of the emissions from the radionuclide increased. Furthermore, there was a strong correlation between the actual dose-rate distribution and the distribution when assuming a uniform source in the kidney for intact antibodies along with medium- to long-range radionuclides, but there was no correlation for small antibody fragments with any radioisotope or for short-range radionuclides with any antibody. However, when the cortex was separated from the whole kidney, the correlation between the actual dose-rate distribution and the assumed dose-rate distribution, if the source was uniform, increased significantly. During radioimmunotherapy, the extent of nonuniformity of dose deposition in the kidney depends on the properties of the antibody and radionuclide. For dosimetry estimates, the cortex should be taken as a separate source region when the radiopharmaceutical is small enough to be filtered by the glomerulus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12537523     DOI: 10.1667/0033-7587(2003)159[0182:tnoadi]2.0.co;2

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  8 in total

1.  177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.

Authors:  Daniel Hubble; Grace Kong; Michael Michael; Val Johnson; Shakher Ramdave; Rodney John Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-06       Impact factor: 9.236

2.  EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.

Authors:  Chaoyu Zhang; Wenjie Sheng; Marwah Al-Rawe; T M Mohiuddin; Marcus Niebert; Felix Zeppernick; Ivo Meihold-Heerlein; Ahmad Fawzi Hussain
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

Review 3.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

4.  Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.

Authors:  Amir Sabet; Khaled Ezziddin; Ulrich-Frank Pape; Karl Reichman; Torjan Haslerud; Hojjat Ahmadzadehfar; Hans-Jürgen Biersack; James Nagarajah; Samer Ezziddin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

5.  Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.

Authors:  Sébastien Baechler; Robert F Hobbs; Andrew R Prideaux; Richard L Wahl; George Sgouros
Journal:  Med Phys       Date:  2008-03       Impact factor: 4.071

6.  Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.

Authors:  Andrew R Prideaux; Hong Song; Robert F Hobbs; Bin He; Eric C Frey; Paul W Ladenson; Richard L Wahl; George Sgouros
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

7.  Correlation between expression of epidermal growth factor receptor and adverse reactions after chemotherapy of advanced non-small-cell lung cancer.

Authors:  Zerui Hao; Chunyan Tian; Futang Yang; Jihong Zhang
Journal:  Pak J Med Sci       Date:  2015 Sep-Oct       Impact factor: 1.088

Review 8.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.